22 research outputs found
Angioimmunoblastic T-cell lymphoma associated Raynaud phenomenon and digital necrosis
No full text9th International Eurasian Hematology Oncology Congress (EHOC) -- OCT 17-20, 2018 -- Istanbul, TURKEYWOS: 000447176600130
A comparison of the statistical treatment of results using concentrations of elements determined by neutron activation and X-ray fluorescence analysis methods
No full textA research on anxiety disorder prevalence and severity among vestibuler migraine and migraine patients
No full textEVALUATION OF BALANCE AND GAIT ABNORMALITIES IN REFRACTORY EPILEPSY: COMPARISON WITH REMISSION EPILEPSY
No full textPOPLITEAL SUBCUTANEOUS MASS AND THYROID INVOLVEMENT AS SIGNS OF EARLY RELAPSE IN PRIMARY TESTICULAR LYMPHOMA
No full text6th International Eurasian Hematology Congress -- OCT 14-18, 2015 -- Antalya, TURKEYWOS: 000373175100126
Diffuse large B cell lymphoma limited to spine
No full text9th International Eurasian Hematology Oncology Congress (EHOC) -- OCT 17-20, 2018 -- Istanbul, TURKEYWOS: 000447176600162
Ranges of 99Mo and 140Ba in several stopping media from the spontaneous fission of 252Cf
No full textPlasma and breast milk pharmacokinetics of tenofovir disoproxil fumarate in nursing mother with chronic hepatitis B-infant pairs
No full textTenofovir use is associated with lower risk of mother-to-infant transmission of the virus, and discontinuation of the treatment is not safe. However, the safety of the drug during pregnancy and breastfeeding is not clear. In this study, we aimed to determine the tenofovir concentration in plasma of mother-infant pairs along with breast milk in chronic hepatitis B patients during the lactation period. A total of 11 mother-infant pairs were enrolled in the study. All the mothers received tenofovir disoproxil fumarate (TDF) 245mg/day for at least 1 month because of chronic hepatitis B infection. Maternal blood, breast milk, and infant blood samples were obtained concomitantly. Tenofovir concentrations were determined by liquid chromatography-tandem mass spectrometry. The median concentrations of tenofovir in maternal plasma and breast milk samples were 88.44 (interquartile range [IQR], 62.47 to 116.17) ng/ml and 6.69 (IQR, 4.88 to 7.03) ng/ml, respectively. Tenofovir concentrations were undetectable (,4ng/ml) in all of the infant plasma samples. The ratio of tenofovir concentration in breast milk to that in maternal plasma was 0.07. Tenofovir disoproxil fumarate passes through the breast milk in a small amount. Infants had no detectable tenofovir level in their plasma. Our study suggests that tenofovir disoproxil fumarate treatment is safe during the breastfeeding period in chronic hepatitis B patients.Viral Hepatitis Society ; Istanbul Universit
